The London-based company said the FDA had approved its lead product Ferracru/Accrufer (ferric maltol) in a market that could be worth $1 billion annually. The FDA approved the product for ...

(Sharecast News) - Shield Therapeutics reported a strong third-quarter performance for its iron deficiency treatment Accrufer in the US on Tuesday, achieving net revenue of $7.2m. The AIM-traded ...

Pharma company Shield Therapeutics has announced a subscription by its largest investor to raise $10m. The company’s main ...

Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer ® /Feraccru ® (ferric maltol). The group has ...

Shield Therapeutics announced on Friday that it has secured a $10m investment from its largest shareholder, AOP Health ...

Strong sales of ACCRUFeR® in the month of October 2024,guidance reiterated to meet the Group revenue covenant target of $31.5 million for the full year 2024 London, UK, 21 November 2024 ...